Director of Department of Medical Research & Gynecologic Cancer Center and Laboratory, Cathay General Hospital;
Professor, School of Medicine, Fu Jen Catholic University
Professor, School of Medicine, Taipei Medical University
1. Gynecologic Oncology 2. Tumor Cell and Molecular Biology 3. Cancer Epigenetics 4. Cancer Stem/ Stromal Progenitor Cell
Phone: (02)26907965 ext 2512 (office) ext2712 (Lab)
Education and Research Experiences：The graduate Institute of Medical Sciences, Ph.D., Taipei Medical University (2004-2008)、Medicine, M.D., China Medical University (1978-1985), Visiting Research Fellow, Duke University Medical Center (1992-1993)
The primary work of gynecologic cancer laboratory emphasized on exploring the HPV induced cervical carcinogenesis and specific genes promoter methylation and signal pathway in gynecologic cancer patients with survival outcome analysis. We especially focus on the mechanism of chemotherapy drug resistance with specific genes promoter methylation in ovarian clear cell cancer stem/ progenitor stromal cells. In the past, we successfully established a platform to examine the high-risk HPV types, integration status, viral loads and mRNA expression levels of HPV deserved for further clinical application, using cervical swab and cervical tissues specimens. Recently, we developed a multiplex high-risk E6 mRNA expression system in comparison with HPV DNA subtypes for the identification of women at risk of cervical cancer. We developed a DNA methylation laboratory technique and platform utilizing ovarian cancer cell lines, tissues, and blood for research. Recently, we successfully cultured two different types (epithelial and mesenchymal) of progenitor stromal cells from ascites and tissues of ovarian cancer patients, and explore the specific genes promoter methylation interaction with drug resistance. We also explored the ovarian tumorigenesis regulated by human ovarian carcinoma stromal progenitor cells which could be inhibited by DNA demethylation agent. We further research on the effect of treatment with demethylating agent in both paclitaxel-sensitive and resistant ovarian clear cell carcinoma and their derived cancer spheroid cells. Hopefully, we can search for the specific target or signal pathway to apply for translational medicine in ovarian cancer patients.